Fluoroquinolone use is the predominant risk factor for the development of a new strain of Clostridium difficile-associated disease

BJU International

Volumn 99, Issue 6, 2007, Pages 1333-1334

  Patel, Nilay S ^a  

^a ROYAL BERKSHIRE HOSPITAL   (United Kingdom)

Author keywords

Clostridium difficile; Diarrhoea; Fluoroquinolones; Urinary tract infection

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CIPROFLOXACIN; GENTAMICIN; METRONIDAZOLE; PENICILLIN G; PROTON PUMP INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TRIMETHOPRIM; VANCOMYCIN; QUINOLONE DERIVATIVE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL FLORA; BACTERIAL INFECTION; BACTERIAL STRAIN; CLOSTRIDIUM DIFFICILE; COLITIS; CYSTITIS; DIARRHEA; DRUG USE; DRUG WITHDRAWAL; HEALTH CARE COST; HOSPITAL INFECTION; HUMAN; HYGIENE; INFECTION PREVENTION; INFECTION RISK; MORTALITY; NOTE; NURSING CARE; ORCHITIS; PRIORITY JOURNAL; PROSTATITIS; PYELONEPHRITIS; SEPSIS; URINARY TRACT INFECTION; ARTICLE; MICROBIOLOGY; PSEUDOMEMBRANOUS COLITIS; RISK FACTOR;

CLOSTRIDIUM DIFFICILE; DIARRHEA; DRUG RESISTANCE, BACTERIAL; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FLUOROQUINOLONES; HUMANS; RISK FACTORS; URINARY TRACT INFECTIONS;

EID: 34447307703     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2006.06741.x     Document Type: Note

References (10)

1. Health Protection Agency. Voluntary reporting of Clostridium difficile, England, Wales and Northern Ireland. Commun Dis Rep CDR Wkly 2004 5 : 15
2. Kuijper EJ, Coignard B, Tull P the ESCMID Study Group for Clostridium difficile (ESGCD)*; EU Member States and the European Centre for Disease Prevention and Control (ECDC). Emergence of Clostridium difficile-associated disease in North America and Europe. Clin Microbiol Infect 2006 12 (Suppl. 6 2 18
3. Pepin J, Valiquette L, Alary ME et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 2004 171 : 466 72
4. Smith A. Outbreak of Clostridium difficile infection in an English hospital linked to hypertoxin-producing strains in Canada and the US. Eurosurveill 2005 10 : E050630.2
5. Warny M, Pepin J, Fang A et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005 366 : 1079 84
6. Health Protection Agency. Clostridium difficile: Findings and recommendations from a review of the epidemiology and a survey of Directors of Infection Prevention and Control in England. Available at: http://www.hpa.org. uk/infections/topics_az/clostridium_difficile/documents/ Clostridium_difficile_survey_findings_recommendations.pdf. Accessed November 2006
7. Pepin J, Saheb N, Coulombe MA et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005 41 : 1254 60
8. Loo VG, Poirier L, Miller MA et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005 353 : 2442 9
9. Linder JA, Huang ES, Steinman MA, Gonzales R, Stafford RS. Fluoroquinolone prescribing in the United States: 1995 to 2002. Am J Med 2005 118 : 259 68
10. Naber KG, Bergman MC, Bjerklund-Johansen TE et al. Guidelines on the Management of Urinary and Male Genital Tract Infections. European Association of Urology. Available at: http://www.uroweb.nl/files/uploaded_files/guidelines/ 15%20Male%20UTI.pdf. Accessed November 2006